- Active not recruitingPHASE3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
This study is for people who have had surgery for bile duct cancer. It's testing a new medicine called rilvegostomig with chemotherapy, to see if it stops the cancer from coming back. It compares the new medicine to a dummy pill.
For: Biliary Tract CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer (squamous non-small cell lung cancer) that has spread. It compares two different drug combinations, including a new medicine called rilvegostomig, to see if they can help patients live longer and improve their quality of life.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study is testing new combinations of medicines for advanced stomach or food pipe cancer that has spread or can't be removed by surgery. It aims to see how well they work and if they are safe. Researchers want to find better ways to treat this type of cancer.
For: Gastric CancerUnited States · China · Japan - RecruitingPHASE3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
This study looks at new drug combinations (Dato-DXd with rilvegostomig) for a type of advanced lung cancer. It compares them to a standard treatment, pembrolizumab, to see if they work better and are safe as a first treatment option.
For: Non-Small Cell Lung CancerUnited States · Australia · Austria - RecruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
For: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal CancerUnited States · Australia · Austria - RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - RecruitingPHASE3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
This study is looking at new treatments for advanced bile duct cancer that has a specific marker called HER2. We want to see if these new medicines work better and are safer than standard treatments for patients who haven't had treatment for their advanced cancer before.
For: Biliary Tract CancerUnited States · Australia · Austria - RecruitingPHASE3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
This study looks at new drug combinations for advanced or returning endometrial cancer that has a specific HER2 marker. It aims to see if these new treatments work better than standard chemotherapy by slowing down cancer growth.
For: Endometrial CancerUnited States · Australia · Austria - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
For: Hepatocellular CarcinomaUnited States · Australia · Brazil - Active not recruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
For: Hepatocellular Carcinoma · Biliary Tract CancerUnited States · China · Hong Kong - RecruitingPHASE2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
This study looks at new treatments for stomach or food pipe cancer that can be removed by surgery. It aims to see how safe and effective these new drugs or drug combinations are before and after the operation.
For: Gastroesophageal AdenocarcinomaUnited States · Canada · China - RecruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
For: Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate CancerUnited States · Canada · China - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
This study is looking at new ways to treat advanced non-small cell lung cancer (a type of lung cancer) that has spread. It compares an experimental drug, rilvegostomig, with a standard drug, pembrolizumab, both given with chemotherapy, to see which works better and is safer.
For: Non-squamous Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
This study is looking at new ways to treat advanced bile duct cancer. It compares two drug combinations: rilvegostomig with chemotherapy, and durvalumab with chemotherapy, to see which is safer and works better as a first treatment.
For: Biliary Tract CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
For: HER2-positive Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
This study is testing a new drug, rilvegostomig, against a standard treatment, pembrolizumab, for advanced lung cancer. It's for people whose cancer has spread and has high levels of a specific marker called PD-L1. The aim is to see which treatment works better and is safer.
For: Carcinoma, Non-Small Cell LungUnited States · Argentina · Australia - RecruitingPHASE3
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
This study is looking at new treatments for a type of bladder cancer that has a high chance of coming back after surgery. It compares two new drugs, Dato-DXd and Rilvegostomig, with standard treatments to see if they are safer and more effective.
For: High-risk Muscle Invasive Urothelial CarcinomaUnited States · Australia · Brazil - RecruitingPHASE2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
This study looks at new drug combinations before and after surgery for early-stage lung cancer. It aims to see if these treatments are safe and work well to help people with non-small cell lung cancer.
For: Non-small Cell Lung CancerUnited States · Belgium · Canada - Active not recruitingPHASE3
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
This study looks at new treatments for early-stage lung cancer after surgery. It compares new drug combinations against standard care to see if they can stop the cancer from coming back, especially in people with higher risk.
For: Non-small Cell Lung CancerUnited States · Brazil · Canada - RecruitingPHASE1, PHASE2
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
This study looks at new and existing treatments for advanced lung cancer (non-small cell type). Researchers are testing different drug combinations to see how safe and effective they are. It aims to find better ways to treat this condition.
For: Advanced or Metastatic Non-small Cell Lung CancerUnited States · Belgium · Brazil